How effective is Bangladesh Ziska Sotorasibu (AMG510)?

Sotoracib (AMG510) is aKRASinhibitor drug, used to treat patients with KRAS G12Cmutated non-small cell lung cancer(NSCLC). Sotoracib isKRAS G12C’s first targeted drug has remarkable effects in the treatment of lung cancer.

Ziskar Bangladesh is a large pharmaceutical company in Bangladesh for 35 years. Currently, Ziskar Pharmaceuticals produces sotoracib and has already been on the market. Ziska Pharmaceuticals is an old pharmaceutical factory in Bangladesh, with more advanced and strict production lines and guaranteed drug quality. According to clinical trials, the drug has a relatively high effectiveness, disease control rate 80.6%, duration of remission 6.8 months, median progression-free survival 13.6 months, and incidence of adverse reactions 69.8%.

The retail price of Ziska Pharmaceuticals in Bangladesh120mg56 capsules3 is about one thousand. If necessary, you can go to the pharmaceutical factory or purchase it through domestic formal channels. The recommended dose for patients with non-small cell lung cancer is 960 mg once daily, continued until disease progression or unacceptable toxicity. Based on individual safety and tolerability, it may be necessary to interrupt dosing or reduce the dose of sotoracil. If dose reduction from 960 mg once daily is necessary, reduce dose to 480 mg once daily. If toxicity recurs at 480 mg once daily, reduce dose to 240 mg once daily. If toxicity occurs at a dose of 240 mg once daily, discontinue use. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.